AOD-9604 vs Semaglutide: Fat Loss Peptides Compared

AOD-9604 and semaglutide are frequently discussed together in weight loss and peptide circles, but they represent entirely different pharmacologic classes with vastly different evidence profiles.

AOD-9604 is a HGH fragment peptide (amino acids 176-191 of human growth hormone) that was developed to stimulate lipolysis without the growth-promoting or insulin-antagonistic effects of full-length HGH. It was designed as a fat-specific compound.

Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1) developed by Novo Nordisk. It activates GLP-1 receptors throughout the body, triggering appetite suppression, delayed gastric emptying, and improved insulin sensitivity. It has FDA approval for diabetes (Ozempic) and weight loss (Wegovy).

The fundamental difference: AOD-9604 targets direct lipolysis; semaglutide targets appetite and metabolic regulation. Their evidence landscapes are entirely different.

Semaglutide clinical evidence:

- Phase 3 trials: STEP 1-4 trials, each enrolling 1,500-1,900 patients - Study duration: 68 weeks of treatment; stratified by baseline weight and comorbidities - Primary endpoints: Percentage weight loss from baseline - Results: 15-22% weight loss (average) compared to 2-3% with placebo - Cardiovascular outcomes: LEADER trial showed 26% reduction in major adverse cardiovascular events - FDA approvals: Ozempic (diabetes, 2017), Wegovy (weight loss, 2021) - Published papers: 50+ peer-reviewed publications; extensively scrutinized in top journals - Real-world data: 2+ years of post-marketing surveillance across millions of patients - Evidence quality: Robust; gold standard

AOD-9604 clinical evidence:

- Phase 2 trials: Multiple small studies (n=20-40) showing lipolysis in vitro and weight reduction in rodent models - Phase 2b trial: ONE human trial (ADAF-0904) comparing AOD-9604 to placebo in overweight/obese subjects - Result: FAILED to meet primary endpoint — no statistically significant difference in fat loss vs placebo - Study was discontinued; no progression to Phase 3 - Published human data: Approximately 3-5 published human studies, all small; most from developer company - Post-market surveillance: Minimal; mostly anecdotal reports and compounding pharmacy use - Evidence quality: Poor to moderate; failed clinical trial is a red flag

The critical difference:

Semaglutide has extensive Phase 3 evidence, FDA approval, and 5+ years of real-world safety data. AOD-9604 failed its pivotal Phase 2b human trial and never advanced. The ADAF-0904 trial failure is the most important clinical fact about AOD-9604.

Semaglutide approval:

- FDA-approved: Yes — Ozempic (GLP-1 RA, type 2 diabetes) and Wegovy (GLP-1 RA, chronic weight management) - Regulatory route: Full FDA approval through Phase 1, 2, 3 trials spanning 15+ years - Mechanism approved: GLP-1 receptor agonism for appetite suppression and metabolic improvement - Market status: Marketed globally; extensive medical infrastructure - Dosing standardization: Pharmaceutical-grade, pen injectors with exact dosing - Safety monitoring: FDA post-market surveillance, pharmacovigilance systems - Insurance coverage: Often covered for diabetes; variable for weight loss

AOD-9604 approval:

- FDA-approved: No - Clinical trial status: Phase 2b trial failed (ADAF-0904); never proceeded to Phase 3 - Mechanism submitted: Direct lipolysis via HGH fragment - Regulatory pathway: Investigational; development halted after Phase 2b failure - Market status: Not approved anywhere; available only as research peptide or compounded product - GRAS status: Designated as Generally Recognized As Safe (GRAS) for food additive use only — NOT as a drug or therapeutic peptide - Current availability: Online peptide suppliers; compounding pharmacies; quality highly variable - Safety monitoring: Essentially none; no post-market surveillance

The GRAS designation for food use does not apply to pharmaceutical use — AOD-9604 as a therapeutic peptide has no regulatory approval.

Semaglutide efficacy (evidence-based):

- Average weight loss: 15-22% of body weight over 68 weeks - Responder rate: 85-90% of patients lose >5% body weight; 70-75% lose >10% - Effect on visceral fat: Preferential reduction in visceral (intra-abdominal) fat - Metabolic effects: Improved HbA1c (5-10% reduction in diabetes), improved lipid profiles - Durability: Weight maintained during continued use; regain if discontinued - Onset: Effects visible at 4-6 weeks; maximal by 16-20 weeks - Mechanism proven: GLP-1 receptor activation confirmed in multiple organ systems

AOD-9604 efficacy (limited data):

- Published animal studies: Stimulates lipolysis in adipocytes; no growth hormone effects - Phase 2b human trial: No statistically significant fat loss vs placebo (ADAF-0904) - Small retrospective reports: Anecdotal weight loss claims, but no controlled data - Proposed mechanism: HGH fragment 176-191 stimulates hormone-sensitive lipase; theoretically sound but clinically unproven in humans - Onset: Unknown; limited human data - Durability: Unknown; no long-term human studies

The critical fact:

The ONE Phase 2b human trial of AOD-9604 failed to show efficacy. This is not a minor setback — Phase 2b failure means the drug did not demonstrate clinical benefit, so development stopped. There are no completed Phase 3 trials showing efficacy.

Choose Semaglutide if:

- You want proven, FDA-approved efficacy (15-22% weight loss from Phase 3 trials) - You need real medical oversight (prescriptions through doctors with monitoring) - You want pharmaceutical-grade medication (exact dosing, consistent quality) - You value long-term safety data (5+ years post-market, 5+ million patients) - You accept cost and side effects (nausea, GI symptoms are common but manageable)

Why avoid AOD-9604:

- Failed clinical trial: The Phase 2b trial did not demonstrate efficacy vs placebo - No human evidence: Zero Phase 3 data; essentially no rigorous human clinical evidence - Regulatory dead-end: Never FDA-approved for any indication; development halted - Quality uncertain: Compounded versions vary widely; no standardization - Risk unknown: No long-term safety data; no post-market surveillance - Cost: $200-400/month for uncertain benefit

Direct comparison:

| Feature | Semaglutide | AOD-9604 | |---------|-----------|----------| | FDA-approved | Yes (Ozempic/Wegovy) | No | | Phase 3 success | Yes (STEP trials) | Never tested | | Published efficacy | 15-22% weight loss | Failed Phase 2b | | Human trial data | 50+ papers; 5+ years | 3-5 papers; anecdotal | | Mechanism proven | Yes (GLP-1 in humans) | Theoretical only | | Real-world evidence | Millions of patients | Unknown | | Safety profile | Well-characterized | Unknown | | Cost | $900-1,400/month | $200-400/month | | Recommendation | Yes | No |

Bottom line:

The evidence strongly favors semaglutide. It has robust Phase 3 efficacy, FDA approval, and years of real-world safety data. AOD-9604, despite its theoretical appeal and lower cost, failed its pivotal human trial and has no clinical evidence of efficacy. Choosing AOD-9604 based on cost or theoretical mechanism is not supported by data.

If semaglutide is unaffordable or contraindicated, explore other GLP-1 agonists (tirzepatide, liraglutide) with proven efficacy rather than AOD-9604.